Endeavor BioMedicines raised a $132.5M oversubscribed Series C financing to advance its precision-medicine pipeline.
APR 24, 2024
Endeavor BioMedicines is a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, focusing on therapies for fibrotic lung diseases
Endeavor BioMedicines is a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, focusing on therapies for fibrotic lung diseases.